{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T05:22:08Z","timestamp":1741324928025,"version":"3.38.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"DOI":"10.4049\/jimmunol.1601645","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T21:25:36Z","timestamp":1479504336000},"page":"4183-4184","source":"Crossref","is-referenced-by-count":3,"title":["Comment on \u201cDNA Sensing via TLR-9 Constitutes a Major Innate Immunity Pathway Activated during Erythema Nodosum Leprosum\u201d"],"prefix":"10.1093","volume":"197","author":[{"given":"Colin L","family":"Crawford","sequence":"first","affiliation":[{"name":"Imperial College of Medicine, Charing Cross Hospital , London W6 8RP,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"2025030618355876300_r1","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.4049\/jimmunol.1600042","article-title":"DNA sensing via TLR-9 constitutes a major innate immunity pathway activated during erythema nodosum leprosum","volume":"197","author":"Dias","year":"2016","journal-title":"J. Immunol."},{"key":"2025030618355876300_r2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(73)92391-X","article-title":"Treatment of erythema nodosum leprosum with thalidomide","volume":"2","author":"Crawford","year":"1973","journal-title":"Lancet"},{"key":"2025030618355876300_r3","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1086\/504295","article-title":"No role for thalidomide in the treatment of leprosy","volume":"193","author":"Crawford","year":"2006","journal-title":"J. Infect. Dis."},{"author":"Center for drug evaluation and research","key":"2025030618355876300_r4","article-title":"Food and Drug Administration"},{"key":"2025030618355876300_r5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jaad.2014.03.034","article-title":"Recognizing and managing the immunologic reactions in leprosy","volume":"71","author":"Kamath","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"author":"Pannikar","key":"2025030618355876300_r6","article-title":"The return of thalidomide.: new uses and renewed concerns"},{"key":"2025030618355876300_r7","first-page":"177","article-title":"Use of thalidomide in leprosy. Adv. Drug React","volume":"134","author":"Crawford","year":"1994","journal-title":"Toxicol. Rev."},{"key":"2025030618355876300_r8"},{"key":"2025030618355876300_r9","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0140-6736(04)16376-9","article-title":"Does thalidomide have a role in leprosy?","volume":"363","author":"Crawford","year":"2004","journal-title":"Lancet"},{"key":"2025030618355876300_r10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jnnp.31.6.543","article-title":"Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study","volume":"31","author":"Fullerton","year":"1968","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2025030618355876300_r11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(69)92660-9","article-title":"Thalidomide neuropathy","volume":"293","author":"The Lancet","year":"1969","journal-title":"Lancet"},{"key":"2025030618355876300_r12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/med\/9780195394702.003.0014","volume-title":"Neuropathic Pain: Mechanisms, Diagnosis and Treatment","author":"Bardia","year":"2012"},{"key":"2025030618355876300_r13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.47276\/lr.87.2.211","article-title":"Experiences with thalidomide for erythema nodosum leprosum- a retrospective study","volume":"87","author":"Darlong","year":"2016","journal-title":"Lepr. Rev."},{"author":"Crawford","key":"2025030618355876300_r14","article-title":"Thalidomide neurotoxicity"},{"key":"2025030618355876300_r15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archderm.1994.01690010070009","article-title":"Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients","volume":"130","author":"Ochonisky","year":"1994","journal-title":"Arch. Dermatol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/197\/11\/4183\/62249979\/1601645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/197\/11\/4183\/62249979\/1601645.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:16:23Z","timestamp":1741288583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/197\/11\/4183\/7973674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1601645","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"type":"print","value":"0022-1767"},{"type":"electronic","value":"1550-6606"}],"subject":[],"published-other":{"date-parts":[[2016,12]]},"published":{"date-parts":[[2016,12,1]]}}}